Swiss officials confirmed that bilateral trade talks with the United States will extend beyond the originally targeted March cutoff, with President Guy Parmelin stating the end-of-month deadline is "de facto" no longer applicable. Parmelin, who also serves as Switzerland's economy minister, told state broadcaster RSI that discussions will carry on into the second quarter.
The postponement follows an earlier provisional agreement reached last year aiming to ease punitive U.S. duties on Swiss imports. The original deal negotiated in November sought to lower the highest U.S. tariff applied to Swiss goods - which had reached 39% - to 15%. That interim understanding, however, has been complicated by subsequent legal and policy shifts in the United States.
Switzerland's trade position was first upended in August, when U.S. President Donald Trump imposed a 39% duty on imports from Switzerland, the largest rate applied by the U.S. to any European country. Bern managed to secure a partial rollback in November, but the course toward a permanent agreement has been disrupted by changes within the U.S. judicial and executive framework.
The situation evolved further in February when the U.S. Supreme Court invalidated the administration's original global tariffs. That development was followed by new U.S. measures that produced a 10% baseline duty and triggered a fresh round of trade inquiries. U.S. authorities launched a new probe earlier this month that includes Switzerland among several major trading partners, creating additional uncertainty over whether the earlier 15% compromise will remain in place.
The uncertain trajectory of tariffs has particular implications for Swiss industries that rely on predictable access to the U.S. market. Sectors producing pharmaceuticals, watches and precision machinery face elevated risk from fluctuating duties and investigations. Analysts cited by Swiss officials say the next scheduled round of talks - expected to take place in April - will be pivotal in determining whether Switzerland retains any preferential tariff status or could be subsumed into a broader global duty scheme.
On the corporate side, Swiss multinationals had been operating under the expectation that a March resolution would stabilize landed costs for exports to the United States. With that resolution delayed, many companies are forced to depend on short-term currency and trade hedging strategies to manage cost volatility. The absence of a finalized treaty continues to leave landed prices in flux, complicating pricing and planning for exporters.
Despite the delay, President Parmelin's comments signal an ongoing commitment to dialogue between Bern and Washington. Both sides appear motivated to avoid reverting to the 39% peak duty, but until negotiators reach a binding agreement or a standstill accord that would shield Swiss exports from the scope of the latest U.S. trade investigations, uncertainty will persist for exporters and investors alike.
Summary
Negotiations to convert a provisional tariff rollback into a permanent Swiss-U.S. agreement have been extended beyond the March target. A November deal reduced U.S. duties from 39% to 15% on an interim basis, but a February U.S. Supreme Court decision and ensuing measures established a new 10% baseline and prompted fresh probes. Talks will continue into the second quarter, with an April session seen as important for the future of Swiss preferential treatment.
Key points
- Negotiations between Switzerland and the United States will continue into the second quarter after the March deadline was effectively dropped - impacting the timeline for finalizing tariff reductions.
- U.S. duties on Swiss imports rose to 39% in August, were provisionally cut to 15% in November, but later U.S. actions established a 10% baseline and prompted new trade investigations.
- High-value Swiss export sectors - notably pharmaceuticals, watches and precision machinery - face ongoing uncertainty, while Swiss multinationals rely on short-term hedging as landed costs remain volatile.
Risks and uncertainties
- Unresolved tariff terms could prolong volatility in costs and pricing for Swiss exporters, affecting margins and cash flow predictability for firms active in the U.S. market - sectors at risk include pharmaceuticals, watches and precision machinery.
- Fresh U.S. trade investigations and the potential loss of a preferential arrangement raise the chance that Switzerland could be subject to a broader global duty framework, increasing tariffs for exporters and complicating market access.
- The absence of a finalized treaty forces companies to depend on short-term currency and trade hedges, which may not fully mitigate landed-cost swings or longer-term commercial planning risks.